Pheochromocytoma
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Drugs by status
Approved for this indication (5)
Phase 4 trials (1)
Phase 3 trials (3)
Phase 2 trials (44)
- 177lu-dota0-tyr3-octreotate
- 18f-mfbg
- gallium-68-dotatate
- 124i-meta-iodobenzylguanidine
- axitinib
- anlotinib
- atezolizumab
- olaparib
- talazoparib
- atenolol
- dovitinib
- fluorodopa
- guadecitabine
- nivolumab
- pembrolizumab
- labetalol
- lenvatinib
- octreotide
- pazopanib
- prazosin
- lanreotide
- propranolol
- zarnestra
- fostamatinib
- ipilimumab
- sunitinib
- temozolomide
- everolimus
- cabozantinib
- dexmedetomidine
- +14 more
Phase 1 trials (10)
Organizations
Organization Involved with Phase 4 Indications (16)
- Maastricht University
- Atrium Medical Center
- Canisius-Wilhelmina Hospital
- Medical Center Haaglanden
- Onze Lieve Vrouw Hospital
- Radboud University
- University of Groningen
- Utrecht University
- Leiden University
- University of Amsterdam
- Free University of Amsterdam
- St. Antonius Hospital, Nieuwegein
- Medisch Spectrum Twente
- Isala Clinics, Zwolle, The Netherlands
- Erasmus University Rotterdam
- Medical Center Leeuwarden
Organization Involved with Phase 3 Indications (12)
- Canadian Cancer Trials Group
- Eastern Cooperative Oncology Group
- Lund University
- New York University
- Southwest Oncology Group
- University of Michigan
- Scandinavian Sarcoma Group
- University of Calgary
- University of California, Los Angeles
- Vancouver Coastal Health
- European Organisation for Research and Treatment of Cancer
- University of Sheffield
Organization Involved with Phase 2 Indications (32)
- Molecular Insight Pharmaceuticals
- Advanced Accelerator Applications
- Roche
- Exelixis
- Pfizer
- Ipsen
- Enterome
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Cancer Institute, Egypt
- National Cancer Institute, France
- University of Pennsylvania
- Cairo University
- Cornell University
- Duke University
- Excel Diagnostics and Nuclear Oncology Center
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Johns Hopkins University
- Seoul National University
- University of Iowa
- University of Ottawa
- University of Toronto
- Mayo Clinic
- Columbia University
- University of California, San Francisco
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- Institut Gustave Roussy
- University of Texas at Houston
- Washington University in St. Louis
- +2 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (13)
- Jubilant DraxImage Inc.
- British Columbia Cancer Agency
- Harvard University
- Emory University
- University of Washington
- Northwell Health
- University of Chicago
- University of Cincinnati
- University of Minnesota
- Cook Children's Medical Center
- Cohen Children's Medical Center of New York
- University of Wisconsin
- University of Colorado